![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
EAST RUTHERFORD, N.J., Oct. 27, 2022 /PRNewswire/ — Cambrex at this time introduced it’s investing in a brand new, 21,000-square-foot analysis and growth facility in Minneapolis, Minnesota, increasing its capability for small molecule growth and manufacturing. Strategically positioned close to the Minneapolis–St. Paul Airport, the brand new facility will specialize in analytical and chemical growth for pharmaceutical drug candidates and will function as an extension of Cambrex’s flagship facility in Charles City, Iowa. Cambrex is anticipated to add roughly 40 new jobs over the subsequent 2-3 years on the new web site in Minneapolis.
Cambrex will concurrently launch a multi-phase, 9,000-square-foot enlargement and 21,000-square-foot renovation challenge in Charles City, Iowa. The enlargement will add a brand new high quality management laboratory and administrative workplace house, which is able to deliver 40 new jobs on the web site. The expansive renovations will improve and modernize the present high quality management and analysis and growth services. The Iowa Economic Development Authority (IEDA) board awarded the corporate tax advantages and $300,000 in direct monetary help to assist the enlargement by way of the High Quality Jobs (HQJ) program.
“Our new facility in Minneapolis will double our analytical and chemical development footprint in the Midwest, providing clients with easy access to state-of-the-art capabilities and top scientific experts,” stated Thomas Loewald, CEO of Cambrex. “We continue to invest in our U.S.-based footprint to support the demand for high-quality API development and manufacturing.”
This funding follows an earlier $50 million enlargement in Charles City that was accomplished in the primary quarter of 2022, establishing Cambrex as the biggest, most superior energetic pharmaceutical ingredient (API) manufacturing web site in the United States. The facility is positioned on a 45-acre property and produces a variety of APIs and pharmaceutical intermediates, together with extremely potent molecules and managed substances.
About Cambrex
Cambrex is a number one world contract growth and manufacturing group (CDMO) that gives drug substance, drug product, and analytical providers throughout your entire drug lifecycle. With over 40 years of expertise and a rising group of over 2,300 consultants servicing world shoppers from North America and Europe, Cambrex is a trusted associate in branded and generic markets for API and completed dosage type growth and manufacturing.
Cambrex provides a spread of specialised drug substance applied sciences and capabilities, together with steady stream, managed substances, solid-state science, materials characterization, stability storage, and extremely potent APIs. In addition, Cambrex can assist standard dosage types, together with oral solids, semi-solids, and liquids, and has the experience to manufacture specialty dosage types resembling modified-release, fixed-dose mixture, pediatric, bi-layer tablets, stick packs, topicals, managed substances, sterile, and non-sterile ointments.
Logo: https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg
View unique content material:https://www.prnewswire.co.uk/news-releases/cambrex-to-invest-16-5-million-in-new-rd-facility-in-minneapolis-minnesota-and-expansion-in-charles-city-iowa-301660237.html
